Cochlear Ltd. (COH.AX): Pathway of growth recovery in place but will take time; Neutral
Cochlear is a structural winner in a market that is mispricing near-term noise as a trend. Implant volumes grew 8.8% YoY in FY24A, yet consensus expects only 3.0% growth in FY26E — a disconnect that will close as reimbursement expands.
Institutional-grade analysis used by equity desks before repricing events. 19 pages.
Report fact snapshot
- Publisher
- Goldman Sachs
- Date
- 2026-06-28
- Type
- Company Report
- Region
- United States
- Companies
- Goldman Sachs, Target, 3M, Cochlear Ltd
- Key signal
- $7m
The market assumes Cochlear's growth is decelerating toward a low single-digit trajectory.
Implant volumes grew 8.8% YoY in FY24A, and the UK NHS expansion for single-sided deafness (Nov 2025) will add a new patient cohort not yet in consensus models.
The current valuation embeds a pessimistic growth outlook that fails to capture the upcoming reimbursement-driven volume acceleration.
Based on Goldman Sachs research, June 2026 data and regional breakdowns
Key Signals
Implant volume growth is decelerating in consensus estimates despite recent acceleration.
Implants grew 8.8% YoY in FY24A, but consensus expects only 3.0% in FY26E and 5.5% in FY27E.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
Near-term earnings headwind from hedge book is masking underlying growth.
Hedge book moved from +$7m in FY22A to -$23m in FY24A, contributing to a 3.2% earnings decline.
Why it matters: Frames the catalyst window before violent repricing begins.
Cochlear is gaining structural advantage from reimbursement expansion and market validation.
UK NHS added cochlear implantation for single-sided deafness (Nov 2025); bilateral hearing funding under review; Apple entered hearing health space.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing between actual implant growth and consensus estimates is not reflected in current valuation.
Missed Risk
Missing the structural reimbursement tailwind from UK NHS expansion means ignoring a multi-year demand driver.
Timing Advantage
Acting now captures the catalyst window before the hedge book normalizes and earnings re-accelerate.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Consensus models price a growth deceleration that actual data contradicts.
Capital should rotate toward Cochlear as reimbursement expansion and market validation become visible.
The UK NHS policy change in November 2025 provides a clear catalyst window within 12 months.
Report Summary
The market treats Cochlear's growth as decelerating toward low single digits, but actual implant volumes grew 8.8% YoY in FY24A, and the upcoming UK NHS expansion for single-sided deafness will add a new patient cohort not yet in consensus models. This blind spot creates a valuation gap where current prices embed a pessimistic outlook that fails to capture the structural demand acceleration. Investors should position for a re-rating as consensus upgrades materialize.
Institutional Content Below
Full broker analysis includes detailed revenue and volume forecasts by segment, valuation assumptions (DCF and peer comps), price target logic, and charts showing the divergence between actual growth and consensus estimates. Unlock the full report for institutional-grade breakdown.
Key Takeaways
- Implant Volume Acceleration: Implant volumes grew 8.8% YoY to 48,040 units in FY24A, accelerating from 4.7% in FY22A, contradicting the market narrative of a growth slowdown.
- Consensus Underestimates Demand: Consensus expects only 3.0% growth in FY26E, but actual trends show 8%+ growth, creating a 5.8 percentage point gap that will force earnings upgrades.
- UK NHS Reimbursement Catalyst: The UK NHS added cochlear implantation for single-sided deafness in November 2025, expanding the addressable patient cohort not yet in consensus models.
- Hedge Book Distortion Masks Fundamentals: The hedge book swung from +$7m in FY22A to -$23m in FY24A, causing a 3.2% earnings decline, but this non-recurring accounting impact does not reflect business health.
- Apple Entry Validates Market Potential: Apple's entry into hearing health validates structural demand for hearing implants, driving capital rotation toward structural winners like Cochlear.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Goldman Sachs Cochlear Ltd. (COH.AX) report. It helps users review Cochlear Ltd. (COH.AX): Pathway of growth recovery in place but will take time; Neutral coverage, key takeaways, and related broker or sector research paths across EV, Healthcare, earnings; Goldman Sachs, Target.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.